Compare AbbVie Inc (ABBV) vs Marqeta Inc (MQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Marqeta Inc — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Marqeta Inc trades at $15.42 (market cap $1.77B). The key difference: AbbVie Inc is far larger — about 254.2× Marqeta Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| ABBV | MQ | |
|---|---|---|
Market Cap | $449.91B | $1.77B |
Sector | Health | Technology |
52-Week High | $261.07 | $27.32 |
52-Week Low | $184.85 | $15.04 |
Enterprise Value | $513.38B | $1.07B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
Marqeta (MQ) trades at $15.93, down 8.63% on the day, with a bullish technical outlook and mixed fundamentals. The stock recently underwent a 4:1 reverse split effective July 1, 2026. Q1 2026 earnings beat expectations with EPS of $0.08 versus -$0.0136 forecast, though Q4 2025 missed. Revenue trends show recovery from 2024's $507M to $625M in 2025, with net income narrowing losses. Analyst consensus is a $19 price target with 32% buy ratings.
The outlook hinges on execution of European expansion and credit product growth, but high P/E of 420.88 reflects significant growth expectations. Risks include ongoing profitability challenges, competitive fintech pressure, and shareholder litigation. Institutional sentiment is cautiously optimistic given the price target upside, but the stock remains speculative until sustained profitability is achieved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
